Skip to content

Research on the transformation system and evaluation of community comprehensive prevention and treatment technology for patients with dyslipidemia

Research on the transformation system and evaluation of community comprehensive prevention and treatment technology for patients with dyslipidemia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070471
Enrollment
Unknown
Registered
2023-04-13
Start date
2018-06-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyslipidemia

Interventions

intervention group:Formulate health management guidelines for dyslipidemia patients at the grassroots level, and conduct training for all grassroots medical personnel
control group:Carry out project implementation management training, and carry out prevention and control work for dyslipidemia management based on the guidance of grassroots medical personnel

Sponsors

Zhejiang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 35-75 years. 2. Meet the diagnostic criteria for dyslipidemia: (1) Without taking lipid-regulating drugs, serum test indicators meet one or more of the following: 1) Total cholesterol (TC) >=6.2mmol/L; 2) Low density lipoprotein cholesterol (LDL-C)>=3.4mmol/L; 3) Triglyceride (TG) >=2.3mmol/L. (2) People with a history of dyslipidemia who are currently taking lipid-regulating drugs. 3. Able to cooperate with project follow-up management and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with acute myocardial infarction or stroke in the past six months; 2. Chronic renal insufficiency, stage 4 and above; 3. Patients with severe hepatic insufficiency (ALT or AST increased more than 3 times the upper limits of normal); 4. The life expectancy is less than 1 year; 5. Participating in other interventional clinical trials.

Design outcomes

Primary

MeasureTime frame
Low density lipoprotein (LDL-C);Proportion of cardiovascular disease with high risk;

Secondary

MeasureTime frame
Control proportion of dyslipid;Percentage of dyslipid patients who received updated treatment in the community;

Countries

China

Contacts

Public ContactYu Wei

Zhejiang Hospital

yuweipost@163.com+86 571 8796 4761

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026